"Hyperphosphatemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Descriptor ID |
D054559
|
| MeSH Number(s) |
C18.452.750.199
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hyperphosphatemia".
Below are MeSH descriptors whose meaning is more specific than "Hyperphosphatemia".
This graph shows the total number of publications written about "Hyperphosphatemia" by people in this website by year, and whether "Hyperphosphatemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperphosphatemia" by people in Profiles.
-
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clin Cancer Res. 2024 Apr 15; 30(8):1466-1477.
-
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. Kidney360. 2024 May 01; 5(5):732-742.
-
Electrolytes disturbances in cancer patients. Curr Opin Nephrol Hypertens. 2022 09 01; 31(5):425-434.
-
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
-
Age and sex effects on FGF23-mediated response to mild phosphate challenge. Bone. 2021 05; 146:115885.
-
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020 11; 31(11):2653-2666.
-
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020 Feb; 7(2):e168-e176.
-
Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease. Pediatr Nephrol. 2018 02; 33(2):325-333.
-
Phosphate Binders: The Evidence Gap Persists. Am J Kidney Dis. 2016 11; 68(5):667-670.
-
Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. J Bone Miner Res. 2016 10; 31(10):1845-1854.